Leuva, H., Graf, R. P., Li, G., Ross, J. S., Zhou, M., Bhatta, S., Vapiwala, N., Pepin, A., Schaffer, K. R., Fojo, A. T. (2026). TP53 mutations (TP53mut) as a predictive biomarker for lutetium-177-PSMA (Lu-PSMA) vs. docetaxel benefit in post-androgen receptor pathway inhibitors (ARPI) metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.28